<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04974515</url>
  </required_header>
  <id_info>
    <org_study_id>20210068</org_study_id>
    <nct_id>NCT04974515</nct_id>
  </id_info>
  <brief_title>Adherence to Electrical Glossal In Situ Stimulation for Sleep Apnea (AEGIS Study)</brief_title>
  <acronym>AEGIS</acronym>
  <official_title>Adherence to Electrical Glossal In Situ Stimulation for Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to assess how well people with mild obstructive sleep apnea&#xD;
      (OSA) adhere to the eXciteOSA device and specifically examine whether adherence of the device&#xD;
      is different with low versus high electrical stimulation. In addition, this research study&#xD;
      will assess how well the device affects mild sleep apnea and if it improves sleepiness and&#xD;
      quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 17, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days device was used</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Adherence level will be reported as the number of days the eXcite OSA device was used</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory event index</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Respiratory event index (events/hr) will be evaluated using a home sleep apnea test. A higher REI indicates greater frequency of abnormal breathing during sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale (ESS) Scores</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Self-reported ESS questionnaire has a total score ranging from 0-24 with the higher score indicating greater daytime sleepiness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Self-reported PSQI has a total score ranging from (0) to (21) with the higher score indicating worse sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-20 (SF-20) Scores</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Self reported SF-20 has a total score ranging from 0-100 with the higher score indicating better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol 5 Dimensions - 5 Levels (EQ-5D-5L) Scores</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Self-reported EQ-5D-5L has a total score ranging from 0 to 100 with the higher score indicating better quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment (WPAI) Questionnaire Scores</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Self-reported WPAI questionnaire has a total score ranging from 0-20 the higher score indicating greater impairment daily activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Snoring Visual Analog Scores</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Partner reported Snoring visual analog has a total score ranging from 0-10 with the higher score indicating greater degree of snoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants accepting long term treatment</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of participants reporting acceptance of long term treatment will be reported</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Low intensity application of eXciteOSA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the eXciteOSA device intervention at low intensity application for 20 minutes per day for 6 consecutive weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High intensity application of eXciteOSA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive the eXciteOSA device intervention at high intensity application for 20 minutes per day for 6 consecutive weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>eXciteOSA</intervention_name>
    <description>eXciteOSA is a device for improving genioglossus endurance through electrical stimulation</description>
    <arm_group_label>High intensity application of eXciteOSA</arm_group_label>
    <arm_group_label>Low intensity application of eXciteOSA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age greater than 18 years&#xD;
&#xD;
          2. Ability to consent&#xD;
&#xD;
          3. Home sleep apnea test demonstrating mild obstructive sleep apnea.&#xD;
&#xD;
          4. Smartphone or tablet&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current pacemaker, defibrillator, or neuro-stimulation device&#xD;
&#xD;
          2. No prior oropharyngeal surgery for sleep apnea&#xD;
&#xD;
          3. No implants, metal prostheses, dental braces, or soft tissue/bony ulcerations in the&#xD;
             oral cavity&#xD;
&#xD;
          4. No prior use of mandibular advancement device (MAD) or continuous positive airway&#xD;
             pressure (CPAP)&#xD;
&#xD;
          5. Heart failure (New York Heart Association Class 3 or 4; or ejection fraction &lt; 45%)&#xD;
&#xD;
          6. Active coronary disease defined as an intervention (e.g., angioplasty, coronary artery&#xD;
             bypass surgery) in the prior 6 months&#xD;
&#xD;
          7. Uncontrolled hypertension (BP &gt; 160/100)&#xD;
&#xD;
          8. Clinician diagnosis of any chronic lung disease except asthma&#xD;
&#xD;
          9. Chronic fatigue syndrome or fibromyalgia&#xD;
&#xD;
         10. Self-reported current illicit drug use in the past 30 days&#xD;
&#xD;
         11. Self-reported use of marijuana or opiates in the past 30 days&#xD;
&#xD;
         12. Use of supplemental oxygen&#xD;
&#xD;
         13. Self-reported use of prescribed or over the counter sleeping medications in the past&#xD;
             30 days&#xD;
&#xD;
         14. Current pregnancy or intention of becoming pregnant&#xD;
&#xD;
         15. Oropharyngeal abnormalities (class 2 or class 3 malocclusion)&#xD;
&#xD;
         16. Periodic breathing (Cheyne Stoke respiration)&#xD;
&#xD;
         17. Central sleep apnea (central apnea index (CAI) &gt; 5/h)&#xD;
&#xD;
         18. Investigator discretion&#xD;
&#xD;
         19. Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Abreu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Alexandre Abreu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

